Komori
Other Disclosures4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Review of the Operating Structure to Strengthen the Management Foundation

Routine and common operations will be consolidated and standardized within the group, and the buildings housing sales offices will be consolidated from 20 locations to 6 locations at the headquarters of the supervisory divisions. The buildings at 14 locations are scheduled to be closed on 31 March 2027, but the sales organization and sales activities themselves will not change.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
14
Number of sales-office buildings to be closed (locations)
Wording
Conditional
How definitive the wording is.

Announced details

Applicable field (uses covered by this announcement)

Routine and highly standardized operations at group companies and locations, and operations supporting sales activities

Launch date31 March 2027 (scheduled)
Relationship between the counterparty and the company
ASKA Pharmaceutical Holdings Co.,Ltd.4886
Relationship with the Company

Review of the business operating structure at each group company and location

Location (as indicated in this announcement)

To remain: Sendai, Saitama, Tokyo (head office), Nagoya, Osaka and Fukuoka. To close: Sapporo, Koriyama, Yokohama, Chiba, Utsunomiya, Niigata, Matsumoto, Kanazawa, Shizuoka, Kyoto, Kobe, Takamatsu, Hiroshima and Kumamoto

Consolidation of sales offices from 20 locations to 6, with buildings at 14 locations to be closed

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Relationship with the CompanyReview of the business operating structure at each group company and location
Launch date31 March 2027 (scheduled)
Applicable areaRoutine and highly standardized operations at group companies and locations, and operations supporting sales activities
LocationTo remain: Sendai, Saitama, Tokyo (head office), Nagoya, Osaka and Fukuoka. To close: Sapporo, Koriyama, Yokohama, Chiba, Utsunomiya, Niigata, Matsumoto, Kanazawa, Shizuoka, Kyoto, Kobe, Takamatsu, Hiroshima and Kumamoto
Location scaleConsolidation of sales offices from 20 locations to 6, with buildings at 14 locations to be closed
Items this document does not state (13)
Names of Products / Services CoveredCounterpartyCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateQuantitative EffectsUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Strengthen the management foundation across the group, optimize the allocation of management resources, improve operational efficiency, and establish an efficient operating structure for sales offices.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Review of the Operating Structure to Strengthen the Management Foundation | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori